Noticias y eventos de Matinas BioPharma Holdings Inc (MTNB)MTNBMatinas BioPharma Holdings Inc

GH Power Confirms TKMS as Preferred Supplier for Canadian Submarine Project

GH Power confirmed that the Government of Canada has selected TKMS as the preferred supplier for the Canadian Patrol Submarine Project, CPSP. As TKMS and the Government of Canada enter formal contract negotiations for the CPSP, GH Power may participate in Industrial and Technological Benefits initiatives as part of TKMS's Canadian industrial strategy. If implemented, GH Power believes that these initiatives could provide it with non-dilutive funding to accelerate the development, validation, and commercialization of its proprietary advanced materials, and clean energy technologies in Canada. Under their existing non-binding memorandum of understanding, GH Power and TKMS are evaluating the integration of GH Power's modular clean energy technology into future defense, industrial, and maritime manufacturing applications. Announcement of GH Power's collaboration with TKMS follows GH Power's recently announced definitive Business Combination Agreement with Matinas BioPharma Holdings. If the proposed transaction is completed, GH Power will become a wholly owned subsidiary of a newly formed Ontario corporation expected to be named GH Power International

Matinas BioPharma Enters Merger with GH Power to Form Clean Energy Company

Matinas BioPharma announced that it has entered into a definitive business combination agreement with GH Power to create a NYSE-listed and publicly-traded critical minerals and clean energy company focused on modular reactors that convert recycled metals into high value advanced materials, clean hydrogen, and usable heat for industrial, utility and distributed energy applications. The company also announced that it has entered into a definitive stock purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT2203 and the company's lipid nano-crystal technology platform, to Azurity Pharmaceuticals. Pursuant to the business combination agreement, a newly formed Ontario corporation expected to be named GH Power International at or prior to the closing of the business combination will become the public parent company of GH Power and Matinas. In the first step, pursuant to a plan of arrangement under Section 182 of the Business Corporations Act, a wholly owned Ontario subsidiary of GHP International will amalgamate with GH Power to form an amalgamated corporation that will be a wholly owned subsidiary of GHP International. Immediately thereafter, a wholly owned Delaware subsidiary of GHP International will merge with and into Matinas, with Matinas surviving as a wholly owned subsidiary of GHP International. GH Power has developed proprietary modular reactor systems that convert scrap metals and water into high-purity alumina, clean hydrogen and thermal energy. Following the closing of the business combination, the combined company is expected to focus on accelerating the commercialization and deployment of GH Power's proprietary technology platform, expanding project development and strategic partnerships across premier markets in North America and Europe, and pursuing commercial deployment opportunities across the clean energy, green hydrogen, industrial decarbonization and critical materials markets. Under the terms of the stock purchase agreement, Azurity will acquire Matinas BioPharma Nanotechnologies, including all rights to MAT2203 and Matinas's LNC technology platform, for $4M in upfront cash consideration, subject to customary adjustments, plus up to an additional $17.5M in potential milestone payments and future mid-single-digit royalties on net sales and certain licensing proceeds generated by MAT2203. Pursuant to royalty rights certificates previously issued to the former holders of Matinas's Series A preferred stock, such holders are entitled to receive, in the aggregate, 7.5% of all amounts received by Matinas from Azurity in connection with the stock sale, including the upfront cash consideration, milestone payments and royalty amounts described above. Consummation of the transaction with Azurity remains subject to the approval of Matinas stockholders and the satisfaction of customary closing conditions, including the satisfaction of the conditions to closing of the business combination with GH Power.

Matinas BioPharma Receives Compliance Notice from NYSE

Matinas BioPharma announced that it received a notice from the NYSE stating that the company is not in compliance with the NYSE American continued listing standards set forth in Section 1003 of the NYSE American Company Guide requiring a company to have stockholders' equity of at least $4M if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, the company had stockholders' equity of $3.02M and has had losses in the most recent five fiscal years ended December 31, 2025.